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Abstract
Background: Studies of pancreaticoduodenectomy (PD) frequently overlook diagnosis as a variable
when evaluating postoperative outcomes or generically group patients according to whether they have
‘benign’ or ‘malignant’ disease. Large multicentre studies comparing postoperative outcomes in PD
stratified by diagnosis are lacking. The present study was conducted to verify the hypothesis that
postoperative morbidity and length of stay (LoS) following PD vary by diagnosis and that patients may be
grouped into low- and high-risk categories.
Methods: The database of the American College of Surgeons National Surgical Quality Improvement
Program (ACS-NSQIP) was reviewed for all PDs performed during 2005–2011. Diagnoses were identified
using ICD-9 codes and grouped based on the incidence of major morbidity. Univariate and multivariate
analyses were utilized to assess the impact of diagnosis on PD outcomes.
Results: Of 5537 patients, those with pancreas cancer (n = 3173) and chronic pancreatitis (n = 485)
experienced similar incidences of major morbidity (P = 0.95) and were grouped as having low-risk
diagnoses. Patients with bile duct and ampullary (n = 1181), duodenal (n = 558) and neuroendocrine (n =
140) disease experienced similar levels of major morbidity (P = 0.78) and were grouped as having high-risk
diagnoses. A high-risk diagnosis was identified as an independent risk factor for a prolonged LoS [odds
ratio (OR) 1.67], organ space infection (OR 2.57), sepsis or septic shock (OR 1.83), and major morbidity
(OR 1.70). Diagnosis did not predict readmission.
Conclusions: The high-risk diagnosis is independently associated with postoperative morbidity and
prolonged LoS. Patients with PD should be stratified by diagnosis to more accurately reflect their risk for
postoperative complications and the complexity of care they will require.
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Introduction
Although significant advancements in the perioperative care of
patients undergoing pancreaticoduodenectomy (PD) have
resulted in a reduction in postoperative mortality, overall postop-
erative morbidity remains high and relatively unchanged.1–6
Several studies have established soft gland texture and small duct
size as consistent predictors of complications after PD.7–12 Impor-
tantly, both of these parameters are associated with considerable
subjectivity as a result of variability in their definitions and meas-
urement. However, the underlying diagnosis prompting surgical
intervention is a non-modifiable, definitive parameter that
appears to have direct association with gland texture and duct size.
Chronic pancreatitis and pancreatic cancer are often characterized
by firmer glands and pancreatic ductal dilation caused by fibrosis,
oedema and ductal obstruction, by contrast with other diagnoses,
such as duodenal, biliary and pancreatic cystic lesions. Classifica-
tion by diagnosis is therefore intriguing as a potential indicator of
risk for the occurrence of postoperative complications. Currently,
studies of postoperative outcomes following PD, including
those using the American College of Surgeons National Surgical
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Quality Improvement Program (ACS-NSQIP) database, fre-
quently overlook diagnosis or group patients into categories
according to whether they have ‘benign’ or ‘malignant’ disease,
rather than performing stratification and analyses by individual
diagnoses.13–15 Grouping patients into ‘benign’ or ‘malignant’ cat-
egories may be overly simple and may lead to the under- or over-
estimation of the true morbidity associated with a given diagnosis
within each category. The averaging effect within each of the
‘benign’ and ‘malignant’ disease groups may encourage the false
impression that no significant differences in morbidity exist
between the two categories. This is because the categories of
‘benign’ and ‘malignant’ both include diagnoses classically associ-
ated with gland textures and duct sizes at each end of the spec-
trum. The present study was conducted with the aim of
developing a more clinically relevant approach towards the iden-
tification of groups at ‘high’ and ‘low’ risk, respectively, for
postoperative complications based on underlying diagnosis. Cur-
rently, several small studies have reported a relationship between
diagnosis and outcomes following PD.7,16–21 However, no large
multicentre study has yet reported on 30-day postoperative out-
comes following PD by diagnosis.
Because of the associations between pathological diagnosis and
pancreatic texture and duct size, and therefore risk for complica-
tions, it can be inferred that patients undergoing PD can be easily
stratified into high- and low-risk groups based on diagnosis alone
without further assessment or calculation. This type of stratifica-
tion is clinically useful as it can be applied at any time in the
clinical course of the patient. Therefore, the present study was
based on the hypotheses that postoperative morbidity and length
of stay (LoS) following PD vary by diagnosis and that patients may
be grouped into low- and high-risk categories.
Materials and methods
Data source
The ACS-NSQIP database is a prospectively maintained, risk-
adjusted outcomes database of 135 variables including 30-day
morbidity and mortality in patients undergoing surgical pro-
cedures. Specific details regarding data collection, outcome vari-
able definitions, quality control and personnel training are
available on the NSQIP website.22
Design
The 2005–2011 ACS-NSQIP Participant Use Data File was
reviewed for all PDs performed between 2005 and 2011. Patients
were identified by Current Procedural Terminology (CPT) codes
48150 and 48153.23 Diagnoses were identified and stratified using
International Classification of Disease, 9th Revision (ICD-9)
codes for: pancreas cancer (157.0, 157.1); chronic pancreatitis
(577.1, 577.8); duodenal neoplasm (152, 152.0, 211.2, 230.7,
235.2); neuroendocrine tumour (157.4, 209.3, 209.30, 209.69,
211.7), and bile duct and ampullary neoplasm (156.1, 156.2,
156.8, 156.9, 211.5, 230.8, 235.3).24
Exclusions
In an attempt to achieve mutually exclusive groups and minimize
any ambiguity of diagnosis, data for patients who were identified
using the aforementioned CPT codes but whose disease did not fit
these ICD-9 codes were excluded. There are no ICD-9 codes
that specifically identify intraductal papillary mucinous
neoplasm (IPMN), serous cystic neoplasm or mucinous cystic
neoplasm. Therefore, no diagnosis group exclusive to IPMN,
serous cystic neoplasm and mucinous cystic neoplasm could
be established. Patients with acute pancreatitis, PD without
pancreaticojejunostomy, or PD with autologous islet cell trans-
plant were excluded. Patients with any of the following preopera-
tive conditions were also excluded: emergent surgery; American
Society of Anesthesiologists (ASA) class 5 status; ventilator
dependence; severe sepsis or septic shock; pneumonia; an open
wound; wound infection; acute renal failure; coma; receipt of
>4 units of red blood cells in the prior 72 h; renal failure; dialysis,
and disseminated cancer. In an attempt to reduce confounding
and to create a sample population that best represents the true
risks associated with PD, patients undergoing concurrent opera-
tions not typically performed with this procedure were also
excluded. Excluded concurrent operations included hepatectomy,
colectomy, hysterectomy, splenectomy, hernia repair, vena cava
resection, nephrectomy, etc. Patients were not excluded for
common concomitant operations, such as feeding tube insertion,
vein resection or reconstruction, vein harvest, central line place-
ment and laparoscopy.
Demographic characteristics
Patient demographic characteristics identified included: gender;
race/ethnicity; age; year of operation; discharge destination; body
mass index (BMI); diabetes; current smoking within 1 year; dys-
pnoea; functional status; history of severe chronic obstructive
pulmonary disease (COPD); congestive heart failure; history of
myocardial infarction within the 6 months prior to operation;
previous percutaneous coronary intervention; previous cardiac
surgery; history of angina within the 1 month prior to surgery;
hypertension requiring medication; steroid use for any chronic
condition; weight loss of >10% of body weight in the previous 6
months; chemotherapy within the 30 days prior to operation;
radiotherapy for malignancy within the 90 days prior to opera-
tion; preoperative creatinine, bilirubin, albumin, alkaline phos-
phatase, haematocrit and international normalized ratio (INR)
values; wound classification, and ASA class.
Outcome variables
Patient outcome variables studied included: total operative time;
30-day mortality; hospital LoS; superficial surgical site infection
(SSI); deep incisional SSI; organ space SSI; any SSI; wound
disruption; pneumonia; unplanned intubation; pulmonary
embolism; ventilator requirement for >48 h; progressive renal
insufficiency; acute renal failure; urinary tract infection (UTI);
stroke or cerebral vascular accident (CVA) with neurological
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deficit; cardiac arrest requiring cardiopulmonary resuscitation
(CPR);myocardial infarction; deep vein thrombosis (DVT); sepsis
or septic shock; reoperation; unplanned readmission; number of
complications; overall morbidity, and total relative value units
(RVUs). For the purpose of this study, a prolonged LoS was indi-
cated by discharge on or after postoperative day (PoD) 14, as
previously defined.25 Transfusion was not investigated as the
outcome variable reported was not consistently collected across all
of the years of the study. Readmission was only available as a
qualitative variable for 2011. Relative value units were reviewed on
a yearly basis and not totalled across all years because there are
year-to-year variations in the assigned RVUs.
Complications and morbidity were then stratified as ‘any’,
‘major’ and ‘minor’. Complications defined as ‘major’ included:
cardiac arrest requiring CPR; myocardial infarction; stroke
or CVA with neurological deficit; wound disruption; deep
incisional SSI; organ space SSI; sepsis or septic shock; unplanned
intubation; ventilator dependency for >48 h; pneumonia; acute
renal failure; progressive renal insufficiency; DVT or thrombo-
phlebitis; pulmonary embolism, and return to the operating
room. Complications defined as ‘minor’ included superficial SSIs
and UTIs.
Statistical analysis
Rates of major morbidity were compared among diagnoses using
chi-squared tests. Diagnoses were then categorized as being of
‘high’ or ‘low’ risk based on the incidence of major morbidity.
Chi-squared tests, Fisher’s exact tests and rank sum tests were
then performed to compare demographic characteristics and
postoperative outcomes in patients in the two risk groups. Mul-
tivariate logistic regression was performed to assess the impact of
diagnosis on outcomes. In an attempt to control for both clini-
cally and statistically significant risk factors, all multivariate
models were adjusted for: age; race; BMI; diabetes status;
smoking status; presence of dyspnoea; functional status; history
of COPD; history of myocardial infarction; weight loss of >10%
of body weight in the 6 months prior to operation; chemo-
therapy within 30 days; radiotherapy within 90 days; preopera-
tive serum albumin; preoperative total bilirubin; preoperative
alkaline phosphatase; preoperative INR; ASA class, and total
operative time quartile. Univariate and multivariate secondary
data analyses were also performed to assess the impacts of other
clinically and statistically significant variables on outcomes. All
statistical analyses were performed using sas Version 9.3 (SAS
Institute, Inc., Cary, NC, USA). A P-value of <0.05 was consid-
ered to indicate statistical significance.
Results
Descriptive statistics: defining high- and low-risk
diagnosis categories
Within the NSQIP database, 5537 patients submitted to PD
during 2005–2011 were identified and included for analysis. These
included 3173 (57.3%) patients with pancreas cancer, 485 (8.8%)
with chronic pancreatitis, 1181 (21.3%) with bile duct or
ampullary neoplasms, 558 (10.1%) with duodenal neoplasms, and
140 (2.5%) with neuroendocrine neoplasms.
Major morbidity was greatest in patients with diagnoses of bile
duct and ampullary neoplasms (33.1%), duodenal neoplasms
(34.6%) and neuroendocrine neoplasms (32.1%). The incidence
of major morbidity did not differ statistically among these three
diagnoses (P = 0.78). Therefore, these three diagnoses were cat-
egorized as being of ‘high’ risk. Incidences of major morbidity
were lowest among patients with pancreas cancer (23.4%) and
chronic pancreatitis (23.3%), and did not differ statistically (P =
0.95). Therefore, pancreas cancer and chronic pancreatitis were
categorized as being of ‘low’ risk (Fig. 1).
Figure 1 Categorizations of high- and low-risk diagnoses based on incidences of major morbidity (any major complication: P < 0.001)
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Demographic characteristics: high- versus
low-risk diagnoses
A comparison between the high- and low-risk diagnosis groups
showed no differences with respect to gender, race, functional
status, cardiac history, hypertension, steroid use, preoperative
haematocrit or preoperative INR (all P > 0.05). High-risk patients
were slightly older, by a median of 1 year, and more likely to have
elevated creatinine or be overweight (BMI 25.0–29.9 kg/m2) or
obese (BMI ≥30 kg/m2). High-risk patients were less likely to have
traditional risk factors for postoperative complications. They were
less likely to have diabetes, to smoke, to have COPD, to have lost >
10% of body weight, to have received neoadjuvant chemotherapy
or radiotherapy, to have preoperative hyperbilirubinaemia, to
have elevated preoperative alkaline phosphatase, to have preop-
erative hypo-albuminaemia, and to have ASA class 3 or 4 status
(Table 1).
Univariate outcome variables: high- versus
low-risk diagnoses
Patients with high-risk diagnoses experienced slightly shorter
operative times. There was no significant difference in postopera-
tive 30-day mortality.
High-risk diagnosis patients were more likely to experience: a
prolonged LoS (≥14 days); superficial SSI; deep SSI; organ space
SSI; any SSI; wound disruption; progressive renal insufficiency;
acute renal failure; UTI; sepsis or septic shock; return to the oper-
ating room; overall morbidity (one or more complications), and
major morbidity. There was no significant difference in readmis-
sion rate (Table 2 and Fig. 2).
Relative value unit: high- versus low-risk diagnoses
The median RVU was observed to increase slightly over time
(Table 2). Median RVU ranged from 47.93 in 2005 to 59.38 in
2011. There was no significant difference in RVU between the
high- and low-risk cohorts except in 2010, for which a higher
median RVU was observed in the low-risk cohort (Table 2).
Major complications: high- versus low-risk diagnoses
Univariate analysis demonstrated that although overall major
morbidity was experienced by 26.8% of all patients studied, those
with a high-risk diagnosis experienced a significantly greater inci-
dence of major morbidity than did patients with low-risk diag-
noses (33.5% versus 23.4%; P < 0.001). Multivariate analysis
revealed the high-risk diagnosis category to be an independent
risk factor for major complications [odds ratio (OR) 1.70, 95%
confidence interval (CI) 1.45–2.00].
Multivariate analysis also revealed other preoperative inde-
pendent risk factors for the occurrence of major complications,
including: age ≥75 years versus 50–64 years (OR 1.47, 95% CI
1.19–1.82); BMI of ≥40 kg/m2 versus 18.5–24.9 kg/m2 (OR 1.93,
95% CI 1.25–2.98); dyspnoea at rest or in moderate exertion (OR
1.46, 95% CI 1.11–1.93); history of myocardial infarction in the 6
months prior to surgery (OR 4.06, 95% CI 1.31–12.53); ASA class
III/IV (OR 1.23, 95% CI 1.02–1.47); and preoperative serum
albumin of < 3.5 g/dl (OR 1.43, 95% CI 1.19–1.72). Fourth-
quartile total operative time (≥7.25 h) in comparison with opera-
tive time of < 4.75 h was also an independent risk factor (OR 1.37,
95% CI 1.09–1.71).
Any SSI: high- versus low-risk diagnoses
On univariate analysis, SSIs were observed in 21.2% of patients.
High-risk diagnosis patients experienced significantly more SSIs
than patients with low-risk diagnoses (28.3% versus 17.5%; P <
0.001). Multivariate analysis revealed the high-risk category to be
an independent risk factor for any SSI (OR 1.78, 95% CI 1.50–
2.11).
Multivariate analysis also revealed other preoperative inde-
pendent risk factors for any SSI including: a BMI of ≥40 kg/m2
versus a BMI of 18.5–24.9 kg/m2 (OR 2.50, 95% CI 1.61–3.87),
and preoperative serum albumin of < 3.5 g/dl (OR 1.37, 95% CI
1.13–1.66). Fourth-quartile total operative time (≥7.25 h) in com-
parison with operative time of < 4.75 h was also an independent
risk factor (OR 1.42, 95% CI 1.13–1.80).
Organ space SSI: high- versus low-risk diagnoses
Organ space infection was observed in 9.6% of all patients
studied. High-risk diagnoses were associated with significantly
more organ space infections than low-risk diagnoses (15.0%
versus 6.8%; P < 0.001). Multivariate analysis revealed a high-risk
diagnosis to be an independent risk factor for organ space SSIs
(OR 2.57, 95% CI 2.02–3.28).
Multivariate analysis also revealed other preoperative inde-
pendent risk factors for organ space SSIs, including: overweight
and obesity at a BMI of 25.0–29.9 kg/m2 (OR 1.38, 95% CI 1.03–
1.84), a BMI of 30.0–34.9 kg/m2 (OR 1.54, 95% CI 1.07–2.22), a
BMI of 35.0–39.9 kg/m2 (OR 1.81, 95% CI 1.10–2.97), and a
BMI of ≥ 40 kg/m2 (OR 2.51, 95% CI 1.38–4.56), all in com-
parison with a BMI of 18.5–24.9 kg/m2. Additionally, preopera-
tive serum albumin of < 3.5 g/dl (OR 1.41, 95% CI 1.06–1.86)
and fourth-quartile total operative time (≥7.25 h) in com-
parison with operative time of < 4.75 h (OR 1.68, 95%
CI 1.19–2.38) were also independent risk factors on multivariate
analysis.
Sepsis and septic shock: high- versus
low-risk diagnoses
A total of 13.7% of all PD patients experienced sepsis or septic
shock. A high-risk diagnosis was associated with a significantly
greater incidence of sepsis and septic shock than a low-risk diag-
nosis (19.1% versus 11.0%; P < 0.001). Multivariate analysis
revealed a high-risk diagnosis to be an independent risk factor for
sepsis and septic shock (OR 1.83, 95% CI 1.49–2.25).
Other preoperative independent risk factors identified in mul-
tivariate analysis included: a BMI of ≥40 kg/m2 versus a BMI of
18.5–24.9 kg/m2 (OR 2.05, 95% CI 1.24–3.39); preoperative
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CPT code, n (%) 0.084
48150 3194 (57.7%) 2080 (56.9%) 1114 (59.3%)
48153 2343 (42.3%) 1578 (43.1%) 765 (40.7%)
Gender, n (%)
Male 2882 (52.1%) 1893 (51.8%) 989 (52.7%) 0.520
Female 2648 (47.9%) 1761 (48.2%) 887 (47.3%)
Race/ethnicity, n (%)
Non-Hispanic White 4293 (77.5%) 2871 (78.5%) 1422 (75.7%) 0.060
Black or African-American 432 (7.8%) 273 (7.5%) 159 (8.5%)
Other or unknown 812 (14.7%) 514 (14.1%) 298 (15.9%)
Age, years, median (IQR) 66 (57–74) 65 (57–73) 66 (57–75) <0.001
Age category, n (%)
<50 years 629 (11.4%) 417 (11.4%) 212 (11.3%) <0.001
50–64 years 1955 (35.3%) 1340 (36.6%) 615 (32.7%)
65–74 years 1687 (30.5%) 1139 (31.1%) 548 (29.2%)
≥75 years 1266 (22.9%) 762 (20.8%) 504 (26.8%)
Discharge destination (from 2011), n (%)
Home/home facility 1227 (85.7%) 836 (86.8%) 391 (83.5%) 0.097
Other 204 (14.3%) 127 (13.2%) 77 (16.5%)
BMI (WHO classification), n (%)
<18.5 kg/m2 188 (3.4%) 145 (4.0%) 43 (2.3%) <0.001
18.5–24.9 kg/m2 2073 (37.8%) 1470 (40.6%) 603 (32.5%)
25.0–29.9 kg/m2 1965 (35.9%) 1240 (34.2%) 725 (39.1%)
30.0–34.9 kg/m2 791 (14.4%) 498 (13.7%) 293 (15.8%)
35.0–39.9 kg/m2 303 (5.5%) 173 (4.8%) 130 (7.0%)
≥40 kg/m2 158 (2.9%) 98 (2.7%) 60 (3.2%)
Diabetes mellitus, n (%)
None 4261 (77.0%) 2719 (74.3%) 1542 (82.1%) <0.001
Insulin or non-insulin/oral 1276 (23.0%) 939 (25.7%) 337 (17.9%)
Current smoker within 1 year, n (%) 1210 (21.9%) 899 (24.6%) 311 (16.6%) <0.001
Dyspnoea at rest/moderate exertion, n (%) 433 (7.8%) 265 (7.2%) 168 (8.9%) 0.026
Functional status partially/totally dependent, n (%) 116 (2.1%) 75 (2.1%) 41 (2.2%) 0.745
History of severe COPD, n (%) 243 (4.4%) 175 (4.8%) 68 (3.6%) 0.045
Congestive heart failure in 30 days prior to surgery, n (%) 15 (0.3%) 8 (0.2%) 7 (0.4%) 0.297
Myocardial infarction in 6 months prior to surgery, n (%) 14 (0.3%) 8 (0.3%) 6 (0.4%) 0.575
Previous PCI, n (%) 317 (6.7%) 204 (6.6%) 113 (7.0%) 0.591
Previous cardiac surgery, n (%) 257 (5.4%) 163 (5.2%) 94 (5.8%) 0.422
Angina in 30 days prior to surgery, n (%) 21 (0.4%) 13 (0.4%) 8 (0.5%) 0.711
Hypertension requiring medication, n (%) 2926 (52.8%) 1914 (52.3%) 1012 (53.9%) 0.279
Steroid use for chronic condition, n (%) 99 (1.8%) 68 (1.9%) 31 (1.6%) 0.578
Loss of > 10% of body weight in 6 months prior to surgery, n (%) 1047 (18.9%) 789 (21.6%) 258 (13.7%) <0.001
Chemotherapy for malignancy in 30 days prior to surgery, n (%) 125 (2.6%) 117 (3.8%) 8 (0.5%) <0.001
Radiotherapy for malignancy in 90 days prior to surgery, n (%) 135 (2.9%) 126 (4.1%) 9 (0.6%) <0.001
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serum albumin of < 3.5 g/dl (OR 1.39, 95% CI 1.10–1.75), and
dyspnoea (OR 1.49, 95% CI 1.06–2.08).
Prolonged LoS: high- versus low-risk diagnoses
High-risk patients experienced significantly longer hospital stays.
A total of 90.0% of low-risk patients were discharged on or before
PoD 19, whereas 90.0% of high-risk patients were discharged by
PoD 23. Of all PD patients, 26.0% were discharged at or after PoD
14. Additionally, high-risk patients had an increased incidence of
prolonged LoS compared with low-risk patients (31.8% versus
23.1%; P < 0.001). Multivariate analysis revealed a high-risk diag-
nosis to be an independent risk factor for a prolonged LoS (OR
1.67, 95% CI 1.41–1.97) (Table 2, Figs 2 and 3).
Other preoperative independent risk factors for a prolonged LoS
identified in multivariate analysis included: age ≥75 years versus
age of 50–64 years (OR 1.58, 95% CI 1.27–1.96), dyspnoea (OR
1.38, 95% CI 1.04–1.83), and preoperative serum albumin of <
3.5 g/dl (OR 1.78, 95%CI 1.48–2.14). Fourth-quartile total opera-
tive time (≥ 7.25 h) in comparison with operative time of < 4.75 h
was also an independent risk factor (OR 1.68, 95% CI 1.34–2.10).
Other patient outcomes: high- versus
low-risk diagnoses
Multivariate analysis identified no differences between the high-
and low-risk diagnosis groups with respect to the occurrence of
UTIs, reoperation, 30-day mortality or readmission.
Discussion
In this analysis of multicentre data, outcomes in 5537 patients
after PD were associated with these patients’ underlying diag-
noses. Although the patients in the low-risk diagnosis group had
an increased incidence of traditional risk factors for postoperative
complications, patients in the high-risk group were identified as
having increased risk for complications including a prolonged
LoS, organ space infection, sepsis or septic shock and major mor-













Preoperative serum creatinine, n (%)
≤1.0 mg/dl 4326 (79.9%) 2927 (81.6%) 1399 (76.6%) <0.001
>1.0 mg/dl to < 1.5 mg/dl 898 (16.6%) 543 (15.1%) 355 (19.4%)
≥1.5 mg/dl 191 (3.5%) 118 (3.3%) 73 (4.0%)
Preoperative serum albumin, n (%)
<3.5 g/dl 1531 (30.4%) 1060 (31.5%) 471 (28.1%) 0.015
≥3.5 g/dl 3509 (69.6%) 2306 (68.5%) 1203 (71.9%)
Preoperative total bilirubin, n (%)
≤1.0 mg/dl 2829 (57.0%) 1760 (53.8%) 1069 (63.3%) <0.001
>1.0 mg/dl to < 2.0 mg/dl 728 (14.7%) 481 (14.7%) 247 (14.6%)
≥2.0 mg/dl 1403 (28.3%) 1030 (31.5%) 373 (22.1%)
Preoperative alkaline phosphatase, n (%)
<120 IU/l 2184 (43.3%) 1323 (39.6%) 861 (50.6%) <0.001
≥120 IU/l 2860 (56.7%) 2019 (60.4%) 841 (49.4%)
Preoperative haematocrit, n (%)
≤24% 27 (0.5%) 16 (0.4%) 11 (0.6%) 0.675
>24% to 35% 1582 (29.2%) 1054 (29.4%) 528 (28.8%)
>35% 3811 (70.3%) 2514 (70.1%) 1297 (70.6%)
Preoperative INR, n (%)
<1.5 4798 (98.6%) 3184 (98.4%) 1614 (99.0%) 0.079
≥1.5 68 (1.4%) 52 (1.6%) 16 (1.0%)
ASA class, n (%)
1–2 (No or mild disturbance) 1653 (29.9%) 1033 (28.3%) 620 (33.0%) <0.001
3–4 (Severe disturbance to life-threatening) 3880 (70.1%) 2623 (71.7%) 1257 (67.0%)
ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; INR, international normalized
ratio; IQR, interquartile range; PCI, percutaneous coronary intervention; WHO, World Health Organization.
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diagnoses (n = 3658)
Patients with high-risk
diagnoses (n = 1879)
P-value
Total operation time, hours, median (IQR) 5.87 (4.72–7.22) 5.93 (4.77–7.33) 5.72 (4.65–7.05) <0.001
Total operation time quartile, n (%)
Q1: < 4.75 h 1411 (25.6%) 896 (24.6%) 515 (27.5%) 0.003
Q2: 4.75 h to < 6 h 1495 (27.1%) 969 (26.6%) 526 (28.1%)
Q3: 6 h to < 7.25 h 1247 (22.6%) 827 (22.7%) 420 (22.4%)
Q4: ≥7.25h 1368 (24.8%) 955 (26.2%) 413 (22.0%)
Total work RVU (primary, concurrent
and other procedures), median (IQR)
2005 47.93 (47.93–54.22) 47.93 (47.93–59.83) 47.93 (47.93–49.13) 0.076
2006 52.91 (47.93–63.28) 53.32 (47.93–64.03) 50.44 (47.93–61.49) 0.160
2007 55.55 (52.63–69.98) 56.83 (52.63–70.99) 55.24 (52.63–69.98) 0.117
2008 57.31 (52.63–71.45) 57.51 (52.63–72.58) 55.25 (52.63–70.22) 0.280
2009 57.72 (52.63–72.60) 58.35 (52.63–72.60) 57.51 (52.63–72.60) 0.778
2010 57.93 (52.84–72.94) 59.38 (52.84–75.41) 55.46 (52.84–71.39) 0.018
2011 59.38 (52.84–72.99) 59.38 (52.84–72.99) 59.38 (52.84–73.92) 0.861
Death within 30 days, n (%) 142 (2.6%) 84 (2.3%) 58 (3.1%) 0.078
Days from operation to discharge
Mean ± SD 12.03 ± 9.20 11.35 ± 7.95 13.36 ± 11.13 <0.001
Median (IQR) 9 (7–14) 9 (7–13) 10 (7–15)
Days from operation to discharge, n (%)
<14 4089 (74.0%) 2811 (76.9%) 1278 (68.2%) <0.001
≥14 1440 (26.0%) 845 (23.1%) 595 (31.8%)
Superficial SSI, n (%) 580 (10.5%) 344 (9.4%) 236 (12.6%) <0.001
Deep incisional SSI, n (%) 137 (2.5%) 76 (2.1%) 61 (3.2%) 0.008
Organ space SSI, n (%) 530 (9.6%) 249 (6.8%) 281 (15.0%) <0.001
Any SSI, n (%) 1173 (21.2%) 641 (17.5%) 532 (28.3%) <0.001
Wound disruption, n (%) 84 (1.5%) 45 (1.2%) 39 (2.1%) 0.015
Pneumonia, n (%) 265 (4.8%) 163 (4.5%) 102 (5.4%) 0.109
Unplanned intubation, n (%) 249 (4.5%) 151 (4.1%) 98 (5.2%) 0.064
Pulmonary embolism, n (%) 50 (0.9%) 29 (0.8%) 21 (1.1%) 0.226
On ventilator for > 48 h, n (%) 252 (4.6%) 157 (4.3%) 95 (5.1%) 0.197
Progressive renal insufficiency, n (%) 36 (0.7%) 15 (0.4%) 21 (1.1%) 0.002
Acute renal failure, n (%) 63 (1.1%) 33 (0.9%) 30 (1.6%) 0.021
Urinary tract infection, n (%) 287 (5.2%) 166 (4.5%) 121 (6.4%) 0.003
Stroke/CVA with neurological deficit, n (%) 17 (0.3%) 15 (0.4%) 2 (0.1%) 0.053
Cardiac arrest requiring CPR, n (%) 63 (1.1%) 38 (1.0%) 25 (1.3%) 0.333
Myocardial infarction, n (%) 37 (0.7%) 26 (0.7%) 11 (0.6%) 0.588
DVT/thrombophlebitis, n (%) 116 (2.1%) 69 (1.9%) 47 (2.5%) 0.130
Sepsis or septic shock, n (%) 759 (13.7%) 401 (11.0%) 358 (19.1%) <0.001
Return to operating room, n (%) 330 (6.0%) 197 (5.4%) 133 (7.1%) 0.012
Readmission (from 2011), n (%) 220 (16.2%) 140 (15.4%) 80 (18.1%) 0.199
Any complications, n (%) 1972 (35.6%) 1166 (31.9%) 806 (42.9%) <0.001
Any major complications, n (%) 1485 (26.8%) 856 (23.4%) 629 (33.5%) <0.001
CPR, cardiopulmonary resuscitation; CVA, cerebral vascular accident; DVT, deep vein thrombosis; IQR, interquartile range; RVU, relative value unit;
SD, standard deviation; SSI, surgical site infection.
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significant increase in the rates of adverse events associated with
diagnosis, there was no corresponding difference in RVU assign-
ment between the high- and low-risk diagnosis groups. Therefore,
this study has considerable implications because diagnosis is a
non-modifiable, independent risk factor for the occurrence of
complications following PD and thus facilitates the calculation of
added requirements for complex care and resource utilization in
high-risk patients.
Recently, there has been increasing interest in risk calculators
for surgery, including PD.12,13,15,26,27 Existing risk calculators for PD
vary based on the parameters suggested as inputs. Some are
designed to include only preoperative variables, whereas others
are meant to use an intraoperative assessment. These calculators
are very useful for aiding pre- and intraoperative decisionmaking,
as well as for providing insight into the relative relationships
among different risk factors. They are, however, subject to several
limitations. Both forms require time and access to the information
required. Preoperative risk calculators require a number of inputs,
many of which may not be known. They also, by their very nature,
are unable to accurately account for critically important variables
such as gland texture and duct size. Diagnoses are either not
considered or are generically grouped as ‘benign’ or ‘malignant’.
Figure 2 Outcomes by diagnosis risk group (all: P < 0.001). LoS, length of stay
Figure 3 Observed rate of hospital discharge by diagnosis risk group (P < 0.001)
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Intraoperative risk calculators include important, albeit subjec-
tive, parameters (i.e. gland texture, estimated blood loss), yet these
are limited by inter-observer variability. Furthermore, external
independent validation of such risk calculators is currently
lacking. Existing calculators may also be too complex to allow for
simple integration into risk stratification systems and the modi-
fication of value assignments. Although risk calculators may prove
to be more sensitive or specific for predicting postoperative com-
plications, their use is certainly more complex than the method of
stratifying by diagnosis alone. As there is a plausible underlying
pathological basis for the inherent risk for complications after PD,
risk calculators should certainly incorporate the influence of diag-
nosis. Further, in an effort to improve the relative value assign-
ment, it may be more prudent to assign additional value to a
patient undergoing PD with a ‘high-risk’ underlying diagnosis
than to base it on the sum of a more subjective risk calculator.
Currently, in the USA, RVUs are assigned by the Relative Value
Update Committee (RUC) to individual operations on the basis of
physician work effort. The Centers for Medicare and Medicaid
Services (www.CMS.gov) provide a physician fee schedule search
tool which allows the RVU for a given CPT to be queried by year.28
For CPT 48150 work, the RVUs assigned varied from 47.93 in
2005 to 52.84 in 2011; likewise, for CPT 48153 work, the RVUs
assigned varied from 47.82 in 2005 to 52.79 in 2011.28 The NSQIP
dataset contains total (index and concurrent operations) work
RVU data, but these have not been utilized to evaluate PD out-
comes. A historical comparison of RVUs assigned for PD as pro-
vided by CMS.gov with the total work RVUs reported by the
NSQIP shows that the RVU assignments from neither source have
increased greatly over time, but that the NSQIP-reported total
RVU has increased at a slightly greater rate than that reported by
CMS.gov for PD. The increase in total RVU reported in the NSQIP
over that seen in the CMS.gov physician fee schedule may poten-
tially be explained by an increase in concurrent operations. For the
purposes of this study, patients with concurrent operations that
are not typically performed with PD were excluded. However,
concurrent operations more typically performed, such as vascular
resection, were included and may potentially explain this differ-
ence although this study did not specifically investigate the inci-
dence of concurrent operations. Its analysis of total work RVU by
diagnosis did demonstrate there to be no relationship between
RVU assignment and diagnosis, complications experienced and,
therefore, resource utilization. These results were anticipated
because there is currently no modification of RVU assignment for
operations, including PD, based on diagnosis, risk or actual com-
plications encountered. Diagnosis, as a non-modifiable independ-
ent risk factor for patient outcomes and resource utilization after
PD,may facilitate a more appropriate assignment of relative value.
Current demands for quality and outcomes improvement
require not only a multidisciplinary team-based approach, but
also proper patient selection and stratification. Patient stratifica-
tion involves the identification of both modifiable and non-
modifiable risk factors, and is essential to developing proper
individualized patient-centred approaches and ensuring high-
quality outcomes. Proper patient stratification is also essential to a
more accurate reflection of outcomes and takes into account case
mix variation. Institutional quality metrics are increasingly used
to assess the care provided. Such quality metrics should therefore
be adjusted for institutional case mix variation. For example, a
case mix consisting primarily of high-risk patients would be
expected to have considerable differences in outcomes, resource
utilization and complexity of care compared with a case mix of
primarily low-risk patients. Furthermore, externally reported per-
formance measures, payer value assignment and performance-
related compensation should also take into account these non-
modifiable risk strata to more accurately account for variation in
case mix and complexity of care.
Limitations
This study has several potential limitations. Firstly, this is a retro-
spective review of a prospective database. Although the ACS has
put in place stringent quality control measures to maintain the
integrity of the data, such datasets are subject to inherent limita-
tions. Additionally, the database does not contain information on
PD-specific variables such as pancreatic fistula, delayed gastric
emptying, pancreas texture and duct size. There are also no
hospital- or surgeon-specific variables to enable comparisons by
volume or experience. This study relies on ICD-9 diagnosis codes
for patient identification and thus only the codes for diagnoses
that are clearly related to the diagnosis categories created can be
studied. The ACS-NSQIP captures only the primary diagnosis and
thus only patients with a primary diagnosis representative of a
diagnosis of interest could be identified. Further, the ICD-9 diag-
nosis information in the ACS-NSQIP is limited to one postopera-
tive diagnosis code per patient. The ACS-NSQIP database does
not contain preoperative diagnoses and as a result no correlation
between pre- and postoperative diagnoses can be made. However,
modern preoperative diagnostic modalities make it increasingly
common to have a correct diagnosis preoperatively.
Several ICD-9 codes were not included because they either did
not translate directly into a defined diagnostic category com-
monly referenced or were not exclusive to one particular diagno-
sis. For example, IPMN, serous cystic neoplasm and mucinous
cystic neoplasm do not have specific ICD-9 codes and therefore
were not evaluated in this study. In addition, although the present
authors assigned codes to the created categories to the best of their
ability, there is no objective way to evaluate the extent to which the
categories are mutually exclusive. Notwithstanding these limita-
tions, however, this is the first large multicentre analysis to
evaluate the impact of diagnosis on postoperative outcomes
following PD.
Conclusions
This study demonstrates that patients undergoing PD can be
easily stratified into high- and low-risk groups based on diagnosis
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alone. This non-modifiable parameter allows a clinically useful
stratification that can be applied at any time in the clinical course
of the patient.
The present findings suggest that future outcomes studies, per-
formance measures, value assignment, and the obtaining of
patient-informed consent for PD should include diagnosis, or
diagnosis risk group, as a predictive factor. The reporting of out-
comes of PD without such stratification may represent a missed
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